Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yoshikazu Inoue"'
Autor:
Toby M. Maher, Wibke Stansen, Yoshikazu Inoue, Vincent Cottin, Kevin K. Brown, Athol U. Wells, Ganesh Raghu, Susanne Stowasser, Kevin R. Flaherty, Arata Azuma, Luca Richeldi, Rozsa Schlenker-Herceg, John T. Huggins
Publikováno v:
Respiratory Medicine. 146:42-48
Background In the INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing of disease progression. We characterised the effects of nintedanib on physiologic outcomes using
Autor:
Hiroyuki Ugai, Takafumi Suda, Rozsa Schlenker-Herceg, Takashi Ogura, Masaki Okamoto, Yoshikazu Inoue, Yasuhiko Nishioka, Tsutomu Takeuchi, Hideya Kitamura, Arata Azuma, Masataka Kuwana, Susanne Stowasser, Ayako Takizawa, Shigeki Makino, Naohiko Inase
Publikováno v:
Respiratory Medicine. 187:106574
Background The efficacy of nintedanib in progressive fibrosing interstitial lung diseases (ILDs) was demonstrated in the randomised, double-blind, placebo-controlled INBUILD trial. This subgroup analysis evaluated the efficacy and safety of nintedani
Autor:
Kevin K, Brown, Kevin R, Flaherty, Vincent, Cottin, Ganesh, Raghu, Yoshikazu, Inoue, Arata, Azuma, John T, Huggins, Luca, Richeldi, Susanne, Stowasser, Wibke, Stansen, Rozsa, Schlenker-Herceg, Toby M, Maher, Athol U, Wells
Publikováno v:
Respiratory medicine. 146
In the INPULSISPost-hoc analyses included changes in FVC over time, cumulative distribution of patients by change in FVC % predicted, and annual rate of decline in FVC in subgroups by diffusing capacity of the lung for carbon monoxide (DLco) and comp
Autor:
Vincent Cottin, Luca Richeldi, Harold R. Collard, Yoshikazu Inoue, Andrew G. Nicholson, Martin Kolb, Florence Le Maulf, David M. Hansell, Ganesh Raghu, Kevin R. Flaherty, Hiroyuki Taniguchi, Susanne Stowasser
Publikováno v:
Respiratory Medicine. 108:1023-1030
Summary Background Nintedanib is in clinical development as a treatment for idiopathic pulmonary fibrosis (IPF). Data from the Phase II TOMORROW study suggested that nintedanib 150 mg twice daily had clinical benefits with an acceptable safety profil
Autor:
Masayuki Hojo, Haruyuki Ishii, Yoshikazu Inoue, Ryushi Tazawa, Takahito Nei, Kazumasa Ohashi, Toshinori Takada, Masanori Yokoba, Koh Nakata, Yasunori Kasahara, Natsuki Motoi, Masahito Ebina, Chinatsu Kaneko, Shinya Urano, Yasuyuki Nasuhara, Hiroko Kanazawa, Ryosuke Eda, Jacqueline A. Kirchner, Toru Arai, Atsuyasu Sato, Etsuro Yamaguchi, Hideaki Nakayama, Yoshiko Tsuchihashi
Publikováno v:
Respiratory Medicine. 106(2):284-293
Summary Background Autoimmune pulmonary alveolar proteinosis (aPAP) is caused by granulocyte/macrophage-colony stimulating factor (GM-CSF) autoantibodies in the lung. Previously, we reported that GM-CSF inhalation therapy improved alveolar-arterial o
Autor:
Yoshikazu Inoue, Ryushi Tazawa, Emi Hamano, Toshihiro Nukiwa, Koh Nakata, Mitsunori Sakatani, Toru Arai
Publikováno v:
Respiratory Medicine. 98:1227-1230
SummaryExistence of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody and treatment with recombinant GM-CSF are new topics in idiopathic pulmonary alveolar proteinosis (PAP). We have hypothesized inhaled GM-CSF is e
Autor:
Richeldi, Luca, Cottin, Vincent, Flaherty, Kevin R., Kolb, Martin, Yoshikazu Inoue, Raghu, Ganesh, Hiroyuki Taniguchi, Hansell, David M., Nicholson, Andrew G., Le Maulf, Florence, Stowasser, Susanne, Collard, Harold R.
Publikováno v:
Respiratory Medicine; 2014, Vol. 108 Issue 7, p1023-1030, 8p
Autor:
Yoshikazu Inoue, Hiroyo Uesugi, Satoru Yamamoto, Toru Arai, Mitsunori Sakatani, Seiji Hayashi, Masanori Akira
Publikováno v:
Respiratory Medicine. (9):1188-1190
SummaryA 29-year-old man with a smoking history of 20 pack years was diagnosed with tuberculosis because Mycobacterium tuberculosis was detected in his gastric juice. His chest radiograph showed multiple nodular opacities on left upper lobe. He was t